MEDP Stock Cash Flow Statements

Medpace Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Medpace Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31

cash flows from operating activities:
net income	90,260,000	114,595,000	117,018,000	96,426,000	88,351,000	102,591,000	78,298,000	70,550,000	61,068,000	72,894,000	68,670,000	66,027,000	49,360,000	61,311,000	50,034,000	48,574,000	39,934,000	43,306,000	50,866,000	41,460,000	24,104,000	28,954,000	29,813,000	23,977,000	27,455,000	19,198,000	22,761,000	19,305,000	16,568,000	14,551,000	11,291,000	9,831,000	9,553,000	8,447,000
adjustments to reconcile net income to net cash from operating activities:
depreciation	6,777,000	6,694,000	7,145,000	7,158,000	6,874,000	6,631,000	6,422,000	6,329,000	5,970,000	5,408,000	5,061,000	4,951,000	4,707,000	4,270,000	4,186,000	4,056,000	3,951,000	3,812,000	3,534,000	2,991,000	2,674,000	2,453,000	2,325,000	2,062,000	1,982,000	1,991,000	2,357,000	2,343,000	2,226,000	2,314,000	2,106,000	2,237,000	2,101,000	2,130,000
amortization	237,000	236,000	361,000	360,000	361,000	361,000	550,000	549,000	550,000	550,000	838,000	838,000	838,000	838,000	1,279,000	1,278,000	1,279,000	1,278,000	1,949,000	1,950,000	1,980,000	1,997,000	2,995,000	2,995,000	2,995,000	5,844,000	7,390,000	7,390,000	7,390,000	7,391,000	9,494,000	9,496,000	9,462,000	9,448,000
stock-based compensation expense	5,951,000	16,892,000	5,889,000	11,727,000	3,588,000	4,310,000	5,165,000	5,007,000	4,906,000	5,438,000	5,593,000	5,794,000	5,653,000	4,372,000	3,981,000	4,047,000	3,570,000	2,871,000	2,961,000	2,762,000	2,616,000	5,445,000	2,707,000	9,466,000	5,385,000	3,183,000	2,113,000	1,432,000	1,487,000	1,467,000	1,248,000	981,000	1,200,000	1,034,000
noncash lease expense	5,623,000	6,064,000	5,819,000	5,844,000	5,765,000	5,696,000	5,067,000	4,920,000	4,902,000	4,757,000	4,555,000	4,501,000	4,422,000	4,537,000	4,410,000	3,979,000	3,996,000	3,903,000	3,956,000	3,680,000	3,371,000	2,917,000	2,737,000	2,425,000	2,424,000	2,363,000
deferred income tax provision	34,107,000	749,000														632,000	1,378,000	1,289,000	-6,384,000	4,495,000	1,337,000	1,079,000	7,211,000	999,000	1,184,000	656,000	-3,318,000
other	-18,000	-502,000	-173,000	67,000	327,000	-4,230,000	1,884,000	1,720,000	556,000	-1,455,000	-1,622,000	438,000	-58,000	-265,000	463,000	82,000	7,000	124,000	63,000	180,000	-198,000	-67,000	-14,000	1,758,000	53,000	-43,000	1,166,000	-256,000	775,000	-32,000	-58,000	129,000	-492,000	-252,000
changes in assets and liabilities:
accounts receivable and unbilled	-79,911,000	-2,069,000	15,274,000	-10,318,000	-21,830,000	19,116,000	-8,968,000	-17,580,000	-17,390,000	-4,344,000	-4,482,000	-23,379,000	-835,000	-38,224,000	64,000	-24,693,000	-1,442,000	1,089,000	-26,930,000	-7,124,000	9,223,000	19,301,000	-15,274,000	9,488,000	-19,725,000	4,255,000	-14,202,000	7,444,000	-2,529,000	-17,760,000	-8,238,000	1,935,000	5,697,000	-2,292,000
prepaid expenses and other current assets	-15,577,000	-17,553,000	-982,000	143,000	-2,046,000	-9,205,000	11,940,000	2,877,000	-1,626,000	-10,205,000	7,222,000	1,392,000	-13,242,000	-5,547,000	12,915,000	-7,160,000	-8,816,000	-6,073,000	6,096,000	-8,960,000	1,834,000	-2,694,000	1,658,000	-5,625,000	-1,772,000	-1,642,000	1,301,000	-1,738,000	-590,000	-214,000	-2,262,000	-752,000	-272,000	-247,000
accounts payable	1,301,000	10,720,000	64,000	-576,000	4,898,000	-7,351,000	1,972,000	-3,262,000	-2,116,000	4,457,000	5,661,000	-1,782,000	3,593,000	-1,041,000	-284,000	2,420,000	2,368,000	-2,638,000	3,014,000	1,562,000	-364,000	-6,809,000	1,912,000	-2,520,000	8,022,000	-2,684,000	2,665,000	-2,698,000	676,000	699,000	5,283,000	2,388,000	-1,524,000	-1,331,000
accrued expenses	35,409,000	-23,160,000	2,949,000	13,018,000	22,047,000	-21,132,000	27,157,000	33,664,000	30,623,000	-9,364,000	4,628,000	32,205,000	19,294,000	-3,651,000	1,465,000	12,754,000	21,980,000	-10,043,000	16,612,000	13,552,000	-4,176,000	-1,757,000	6,397,000	9,361,000	11,287,000	-5,221,000	7,416,000	7,429,000	8,916,000	5,268,000	3,527,000	3,558,000	2,110,000	-10,508,000
advanced billings	90,067,000	8,131,000	39,646,000	32,522,000	21,720,000	56,837,000	41,105,000	28,198,000	24,517,000	3,311,000	44,802,000	16,559,000	34,147,000	22,580,000	40,793,000	21,631,000	4,410,000	22,143,000	53,052,000	7,261,000	5,789,000	-2,695,000	22,683,000	4,355,000	15,109,000	2,437,000	7,316,000	12,431,000	9,029,000	6,817,000	5,354,000	2,675,000	4,952,000	-5,246,000
lease liabilities	-6,067,000	-6,548,000	-5,990,000	-4,392,000	-5,079,000	-5,946,000	-4,440,000	-5,054,000	-4,095,000	-5,284,000	-4,765,000	-3,429,000	-4,163,000	-3,542,000	-4,297,000	-3,379,000	-4,801,000	-3,155,000	-3,999,000	-2,574,000	-2,697,000	-2,236,000	-2,557,000	-2,139,000	-2,297,000	-2,041,000
other assets and liabilities	-19,633,000	11,587,000	27,845,000	-1,390,000	-8,525,000	5,864,000	4,052,000	-5,934,000	-22,701,000	14,976,000	21,566,000	5,218,000	-6,216,000	1,486,000	-3,537,000	8,299,000	-4,886,000	-420,000	883,000	-1,297,000	-1,051,000	3,441,000	-5,453,000	7,811,000	-6,008,000	5,771,000	2,530,000	-1,173,000	-2,521,000	3,089,000	1,724,000	1,253,000	-2,079,000	1,884,000
net cash from operating activities	148,526,000	125,836,000	190,666,000	149,075,000	116,397,000	152,677,000	156,395,000	114,385,000	82,518,000	80,076,000	136,684,000	108,491,000	96,619,000	46,256,000	70,894,000	72,353,000	62,761,000	57,319,000	105,498,000	59,763,000	44,267,000	49,148,000	56,940,000	64,292,000	46,630,000	34,005,000	39,442,000	52,501,000	41,343,000	23,298,000	28,652,000	39,000,000	30,408,000	-675,000
capex	0	0	2,299,000	-851,000	-1,809,000	5,345,000	550,000	-1,144,000	-1,368,000	7,216,000	-1,256,000	1,653,000	0	0	928,000	-400,000	0	0	8,248,000	-965,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0
free cash flows	148,526,000	125,836,000	192,965,000	148,224,000	114,588,000	158,022,000	156,945,000	113,241,000	81,150,000	87,292,000	135,428,000	110,144,000	96,619,000	46,256,000	71,822,000	71,953,000	62,761,000	57,319,000	113,746,000	58,798,000	44,267,000	49,148,000	56,940,000	64,292,000	46,630,000	34,005,000	39,442,000	52,501,000	41,343,000	23,298,000	28,652,000	39,000,000	30,408,000	-675,000
cash flows from investing activities:
property and equipment expenditures	-6,113,000	-9,994,000	-7,643,000	-10,537,000	-12,871,000	-5,497,000	-9,986,000	-8,703,000	-8,446,000	-9,513,000	-9,243,000	-7,179,000	-11,200,000	-9,257,000	-9,116,000	-6,640,000	-6,008,000	-6,507,000	-7,786,000	-8,669,000	-9,324,000	-5,561,000	-5,760,000	-6,162,000	-3,470,000	-2,520,000	-3,449,000	-2,782,000	-5,842,000	-3,951,000	-3,395,000	-2,310,000	-1,645,000	-4,374,000
net cash from investing activities	-6,020,000	-9,987,000	-7,562,000	-10,486,000	-12,790,000	2,530,000	-7,997,000	-8,662,000	-8,467,000	-9,503,000	-9,220,000	-7,187,000	-11,127,000	-11,208,000	-9,116,000	-6,600,000	-5,997,000	-9,651,000	-7,734,000	-8,643,000	-9,315,000	-5,522,000	-5,730,000	-6,132,000	-3,440,000	-3,842,000	-4,212,000	-2,790,000	-6,043,000	-3,928,000	-3,383,000	-2,349,000	-2,147,000	-4,358,000
cash flows from financing activities:
proceeds from stock option exercises	351,000	25,934,000	1,258,000	6,274,000	666,000	7,660,000	1,523,000	5,728,000	1,664,000	2,463,000	5,761,000	892,000	1,554,000	13,867,000	2,431,000	1,012,000	5,098,000	9,102,000	7,239,000	6,777,000	645,000	1,331,000	834,000	1,795,000	2,919,000	972,000	679,000	635,000	609,000	566,000	625,000	232,000	762,000	193,000
repurchases of common stock	-540,915,000	-371,900,000					0	0	-23,874,000	-120,146,000	-47,182,000	0	-374,717,000	-425,950,000	0	-6,219,000			-47,447,000	0	-9,051,000	-41,776,000									-60,323,000	-68,855,000
net cash from financing activities	-540,564,000	-345,966,000	-168,609,000	6,274,000	666,000	7,660,000	1,523,000	-49,272,000	-82,210,000	-52,683,000	-131,121,000	-109,108,000	-123,463,000	-412,083,000	2,431,000	-5,207,000	-50,779,000	9,102,000	-40,208,000	6,777,000	-8,406,000	-40,445,000	834,000	1,795,000	-53,519,000	-23,028,000	-33,847,000	-49,748,000	-33,975,000	-24,010,000	-23,234,000	-42,144,000	-29,145,000	-3,305,000
effect of exchange rates on cash, cash equivalents, and restricted cash	2,952,000	2,117,000	-1,959,000	1,143,000	-389,000	-1,306,000	321,000	-382,000	375,000	767,000	915,000	-3,740,000	-2,321,000	-1,426,000	-1,292,000	-1,168,000	147,000	-1,659,000	983,000	427,000	358,000	-1,102,000	586,000	-763,000	300,000	-290,000	-352,000	51,000	-1,340,000	400,000	210,000	410,000	605,000	540,000
increase in cash, cash equivalents, and restricted cash	-395,106,000	-228,000,000	12,536,000	146,006,000	103,884,000	161,561,000	150,242,000	56,069,000	-7,784,000	18,657,000	-2,742,000	-11,544,000	-40,292,000	-378,461,000	62,917,000	59,378,000	6,132,000	55,111,000	58,539,000	58,324,000	26,904,000	2,079,000	52,630,000			6,845,000					2,245,000			-7,798,000
cash, cash equivalents, and restricted cash — beginning of period	0	669,436,000	0	0	0	245,449,000	0	0	0	28,265,000	0	0	0	461,304,000	0	0	0	277,766,000	0	0	0	131,920,000	0	0	0	23,282,000	0	0	0	26,492,000	0	0	0	37,407,000
cash, cash equivalents, and restricted cash — end of period	-395,106,000	441,436,000	12,536,000	146,006,000	103,884,000	407,010,000	150,242,000	56,069,000	-7,784,000	46,922,000	-2,742,000	-11,544,000	-40,292,000	82,843,000	62,917,000	59,378,000	6,132,000	332,877,000	58,539,000	58,324,000	26,904,000	133,999,000	52,630,000	59,192,000	-10,029,000	30,127,000	1,031,000	14,000	-15,000	22,252,000	2,245,000	-5,083,000	-279,000	29,609,000
supplemental disclosure of cash flow information —
share repurchases—non-cash		22,343,000
deferred income tax benefit			-24,199,000	-1,514,000	-54,000	-865,000	-13,809,000	-7,599,000	-2,646,000	-1,063,000	-20,888,000	-687,000	-726,000	-713,000															-38,000	-248,000		444,000	-454,000	-410,000
proceeds from revolving loan							0	0	15,000,000	90,000,000	25,000,000	0	249,700,000	49,500,000																	60,000,000
payments on revolving loan							0	-55,000,000	-75,000,000	-25,000,000	-114,700,000	-110,000,000	0	-49,500,000													0	-20,000,000	-30,000,000	-20,000,000	-20,000,000
supplemental disclosure of cash flow information—
cash paid during the period for income taxes
cash paid during the period for interest
acquisition of property and equipment—non-cash			2,299,000	-851,000	-1,809,000	5,345,000	550,000	-1,144,000	-1,368,000	7,216,000	-1,256,000	1,653,000			928,000	-400,000			8,248,000	-965,000
amortization and adjustment of deferred credit											-155,000	-155,000	-155,000	-155,000	-167,000	-167,000	-167,000	-167,000	-175,000	-175,000	-175,000	-181,000	-200,000	-201,000	-200,000	-200,000	-197,000	-7,108,000	-204,000	-203,000
acquistion of property and equipment—non-cash														7,375,000
amortization of debt issuance costs and discount																							0	80,000	736,000	138,000	144,000	154,000	158,000	159,000	164,000	166,000	167,000	165,000
payment of debt																							0	0	-56,438,000	-24,000,000	-34,032,000	-29,906,000	-4,125,000	-4,125,000	-3,094,000	-3,094,000	-3,093,000	-3,094,000
payment of deemed landlord liability																											-494,000	-477,000	-459,000	-451,000	-442,000	-427,000	-409,000	-404,000
pre-funded study costs																															4,143,000	4,659,000	-13,000	-3,497,000
acquisition of intangibles																															0	-54,000
decrease in cash, cash equivalents, and restricted cash																												14,000	-15,000	-4,240,000
loss on extinguishment of debt
payment for common stock issuance costs
excess tax benefit from stock-based compensation
proceeds from issuance of debt, net of original issue discount
debt issuance costs
payment on debt extinguishment
proceeds from common stock issued
impairment of goodwill
proceeds from common stock issued, net of underwriters discount
restricted cash
effect of exchange rates on cash and cash equivalents
decreases in cash and cash equivalents
cash and cash equivalents — beginning of period
cash and cash equivalents — end of period
acquisition of predecessor, net of cash and restricted cash received
payment on revolving loan

We provide you with 20 years of cash flow statements for Medpace stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Medpace stock. Explore the full financial landscape of Medpace stock with our expertly curated income statements.

The information provided in this report about Medpace stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.